Oncology
Advanced ROS1-positive NSCLC
Expert Roundtables Podcast: Next-Generation Tyrosine Kinase Inhibitors for ROS1-Positive Non–Small Cell Lung Cancer
Although currently available ROS1 TKIs demonstrate high response rates for non–small cell lung cancer, some limitations do exist, including acquired resistance, central nervous system penetrance, and drug-related toxicities. In today’s podcast, our experts discuss recent data on next-generation TKIs and the trajectory of TKI therapy for this patient population.
Boulanger MC, Schneider JL, Lin JJ. Advances and future directions in ROS1 fusion-positive lung cancer. Oncologist. 2024;29(11):943-956. doi:10.1093/oncolo/oyae205
Desilets A, Repetto M, Yang SR, Drilon A. Targeting ROS1 rearrangements in non–small cell lung cancer: current insights and future directions. Cancer. 2025;131(suppl 1):e35784. doi:10.1002/cncr.35784
Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers – biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35-55. doi:10.1038/s41571-020-0408-9
Fabbri L, Di Federico A, Astore M, et al. From development to place in therapy of lorlatinib for the treatment of ALK and ROS1 rearranged non-small cell lung cancer (NSCLC). Diagnostics (Basel). 2023;14(1):48. doi:10.3390/diagnostics14010048
Gendarme S, Bylicki O, Chouaid C, Guisier F. ROS-1 fusions in non-small-cell lung cancer: evidence to date. Curr Oncol. 2022;29(2):641-658. doi:10.3390/curroncol29020057
Horton C, Hoang L, Zimmermann H, et al. Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. JAMA Oncol. 2024;10(2):212-219. doi:10.1001/jamaoncol.2023.5586
Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV ROS1-rearranged non–small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.001
Pérol M, Li W, Lai RK, Zhou C. Reply to: “Baseline brain metastasis imbalance in TRUST: implications for interpreting intracranial efficacy of taletrectinib” and “Taletrectinib in ROS1 fusion–positive non–small cell lung cancer: promising yet premature?” J Clin Oncol. 2025;43(29):3227-3228. doi:10.1200/JCO-25-01448
Rothschild SI, Mauti LA. ROS1 fusion-positive non-small cell lung cancer—repotrectinib as a new treatment option. Transl Cancer Res. 2025;14(6):3272-3276. doi:10.21037/tcr-2025-263
Wolf J, Goring S, Lee A, et al. Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC. Cancers (Basel). 2025;17(5):748. doi:10.3390/cancers17050748
Explore More in Advanced ROS1-positive NSCLC
Advanced ROS1-positive NSCLC
Overcoming Acquired Resistance in ROS1-Positive Metastatic Non–Small Cell Lung Cancer
Advanced ROS1-positive NSCLC
Optimizing Molecular Testing to Identify Driver Mutations in Advanced Non–Small Cell Lung Cancer
Advanced ROS1-positive NSCLC
Molecular Testing in Advanced Non–Small Cell Lung Cancer: Detecting Complex Rearrangements
Advanced ROS1-positive NSCLC